Sandbox Rim: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 4: | Line 4: | ||
<span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span> | <span style="font-size:85%">Boxes in the red color signify that an urgent management is needed.</span> | ||
{{Family tree/start}} | {{Family tree/start}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A00 | | A00=<div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A00 | | A00=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Identify cardinal findings of unstable angina/ NSTEMI :''' <br> | ||
❑ '''[[Chest pain|<span style="color:white;"> Chest pain</span>]] or [[chest discomfort|<span style="color:white;">chest discomfort</span>]]''' <br> | ❑ '''[[Chest pain|<span style="color:white;"> Chest pain</span>]] or [[chest discomfort|<span style="color:white;">chest discomfort</span>]]''' <br> | ||
:❑ Sudden onset | :❑ Sudden onset | ||
Line 22: | Line 22: | ||
❑ '''Increase in >99th percentile of upper limit of normal of [[troponin|<span style="color:white;">troponin</span>]] and / or [[CKMB|<span style="color:white;">CK MB </span>]]''', which is consistent with [[NSTEMI|<span style="color:white;">NSTEMI</span>]]</div>}} | ❑ '''Increase in >99th percentile of upper limit of normal of [[troponin|<span style="color:white;">troponin</span>]] and / or [[CKMB|<span style="color:white;">CK MB </span>]]''', which is consistent with [[NSTEMI|<span style="color:white;">NSTEMI</span>]]</div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | G02 | G02= <div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | G02 | G02= <div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Rule out life threatening alternative diagnoses:'''<br> | ||
❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]] <br> (suggestive findings: [[back pain|<span style="color:white;">back pain</span>]], [[interscapular pain|<span style="color:white;">interscapular pain</span>]], [[aortic regurgitation|<span style="color:white;">aortic regurgitation</span>]], [[pulsus paradoxus|<span style="color:white;">pulsus paradoxus</span>]], [[blood pressure|<span style="color:white;">blood pressure</span>]] discrepancy between the arms) <br> | ❑ [[Aortic dissection|<span style="color:white;">Aortic dissection</span>]] <br> (suggestive findings: [[back pain|<span style="color:white;">back pain</span>]], [[interscapular pain|<span style="color:white;">interscapular pain</span>]], [[aortic regurgitation|<span style="color:white;">aortic regurgitation</span>]], [[pulsus paradoxus|<span style="color:white;">pulsus paradoxus</span>]], [[blood pressure|<span style="color:white;">blood pressure</span>]] discrepancy between the arms) <br> | ||
❑ [[Pulmonary embolism|<span style="color:white;">Pulmonary embolism</span>]] <br> (suggestive findings: acute onset of [[dyspnea|<span style="color:white;">dyspnea</span>]], [[tachypnea|<span style="color:white;">tachypnea</span>]], [[hemoptysis|<span style="color:white;">hemoptysis</span>]], previous [[DVT|<span style="color:white;">DVT</span>]]) <br> | ❑ [[Pulmonary embolism|<span style="color:white;">Pulmonary embolism</span>]] <br> (suggestive findings: acute onset of [[dyspnea|<span style="color:white;">dyspnea</span>]], [[tachypnea|<span style="color:white;">tachypnea</span>]], [[hemoptysis|<span style="color:white;">hemoptysis</span>]], previous [[DVT|<span style="color:white;">DVT</span>]]) <br> | ||
Line 29: | Line 29: | ||
❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}} | ❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: 20em; padding:1em;">'''Begin initial treatment:'''<br> ❑ Administer [[aspirin|<span style="color:white;">aspirin</span>]] (I-A) | ||
:❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN | :❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN | ||
:❑ 75 to 325 mg/day | :❑ 75 to 325 mg/day | ||
Line 48: | Line 48: | ||
</div>}} | </div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | G01 | G01= <div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | G01 | G01= <div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Does the patient have any of the following indications that require immediate angiography and revascularization ?''' | ||
❑ Hemodynamic instability or [[cardiogenic shock|<span style="color:white;">cardiogenic shock </span>]] <br> | ❑ Hemodynamic instability or [[cardiogenic shock|<span style="color:white;">cardiogenic shock </span>]] <br> | ||
❑ Severe left ventricular dysfunction or [[heart failure|<span style="color:white;">heart failure </span>]] <br> | ❑ Severe left ventricular dysfunction or [[heart failure|<span style="color:white;">heart failure </span>]] <br> | ||
Line 56: | Line 56: | ||
❑ Prior [[PCI|<span style="color:white;">PCI </span>]] within past 6 months or [[CABG|<span style="color:white;">CABG </span>]] <br> </div> }} | ❑ Prior [[PCI|<span style="color:white;">PCI </span>]] within past 6 months or [[CABG|<span style="color:white;">CABG </span>]] <br> </div> }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |,|-|-|^|-|-|.| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |,|-|-|^|-|-|.| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | C01 | | | | C02 | | | C01=<div style="float: left; text-align: center; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | C01 | | | | C02 | | | C01=<div style="float: left; text-align: center; width: 20em; padding:1em;">'''YES''' </div>| C02= <div style="float: left; text-align: center; width: 20em; padding:1em;">'''NO''' </div> }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | |!| | | | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | |!| | | | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | C03 | | | C03=<div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | | | C03 | | | C03=<div style="float: left; text-align: left; width: 20em; padding:1em;">Does the patient have negative ECG findings AND negative biomarkers?</div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|^|-|.| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|^|-|.| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | C04 | | C05 | C04= Yes | C05= No}} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | C04 | | C05 | C04= Yes | C05= No}} | ||
Line 66: | Line 66: | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| C07 | | C08 |!| C07= ECG and biomarkers are both negative | C08= At least one (ECG or biomarkers) is positive}} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| C07 | | C08 |!| C07= ECG and biomarkers are both negative | C08= At least one (ECG or biomarkers) is positive}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| |!| | | |!| |!| }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| |!| | | |!| |!| }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!|C09 | | | C10 | | | C09= <div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!|C09 | | | C10 | | | C09= <div style="float: left; text-align: left; width: 20em; padding:1em;">[[Chest pain resident survival guide#Complete Diagnostic Approach|Proceed to complete diagnostic approach of chest pain to rule out differential diagnoses]]</div>| C10=<div style="float: left; text-align: left; width: 20em; padding:1em;">'''Calculate the risk of future adverse clinical outcomes:'''<br> | ||
❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR | ❑ [[TIMI risk score|<span style="color:white;">Thrombolysis in Myocardial Infarction (TIMI) risk score</span>]], OR | ||
❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div>}} | ❑ [[GRACE score|<span style="color:white;">GRACE score</span>]] </div>}} | ||
Line 73: | Line 73: | ||
| D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Intermediate or high risk''' <br> '''Initial invasive strategy''' </div>| D03= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Low risk''' <br> '''Initial conservative strategy''' </div>}} | | D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Intermediate or high risk''' <br> '''Initial invasive strategy''' </div>| D03= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Low risk''' <br> '''Initial conservative strategy''' </div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 20em; padding:1em;"> | ||
'''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br> | '''Administer ONE of the following antiplatelet agents (before or at the time of PCI):''' <br> | ||
❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br> | ❑ Loading dose of [[P2Y12|<span style="color:white;">P2Y12</span>]] receptor inhibitors <br> | ||
Line 140: | Line 140: | ||
:❑ Maintenance dose for up to 12 months (90 mg twice daily)</div>}} | :❑ Maintenance dose for up to 12 months (90 mg twice daily)</div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | F01 | | F02 | | F03 | |F01=<div style="float: left; text-align: left; width: | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | F01 | | F02 | | F03 | |F01=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Consider urgent [[CABG|<span style="color:white;">CABG</span>]] if the coronary anatomy is not amenable to PCI and one of the following:'''<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = | title = ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=15466654 | publisher = | date = | accessdate = }}</ref> <br> ❑ Patients with left main or left main equivalent disease <br> ❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction <br> ❑ Diabetic patients </div>|F02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> ❑ Perform an [[angiography|<span style="color:white;">angiography</span>]] </div>|F03='''Does the patient experience any of the following?''' <br> | ||
❑ Recurrence of symptoms<br> | ❑ Recurrence of symptoms<br> | ||
❑ [[Heart failure|<span style="color:white;">Heart failure</span>]]<br> | ❑ [[Heart failure|<span style="color:white;">Heart failure</span>]]<br> |
Revision as of 02:42, 7 April 2015
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention based on the 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction.[1]
Boxes in the red color signify that an urgent management is needed.
Identify cardinal findings of unstable angina/ NSTEMI : ❑ Chest pain or chest discomfort
❑ Characteristic ECG changes consistent with unstable angina/ NSTEMI
| |||||||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection (suggestive findings: vomiting, subcutaneous emphysema) | |||||||||||||||||||||||||||
Begin initial treatment: ❑ Administer aspirin (I-A)
❑ Administer 2-4 L/min oxygen via nasal cannula when saturation <90%
❑ Administer beta-blockers (unless contraindicated) and titrate to the heart rate and blood pressure
❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
❑ Administer 80 mg atorvastatin | |||||||||||||||||||||||||||
Does the patient have any of the following indications that require immediate angiography and revascularization ?
❑ Hemodynamic instability or cardiogenic shock | |||||||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||||||
Does the patient have negative ECG findings AND negative biomarkers? | |||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||
Repeat ECG and biomarkers within next 6 hours and 12 hours | |||||||||||||||||||||||||||
ECG and biomarkers are both negative | At least one (ECG or biomarkers) is positive | ||||||||||||||||||||||||||
Calculate the risk of future adverse clinical outcomes: ❑ Thrombolysis in Myocardial Infarction (TIMI) risk score, OR ❑ GRACE score | |||||||||||||||||||||||||||
Proceed to angiography | Intermediate or high risk Initial invasive strategy | Low risk Initial conservative strategy | |||||||||||||||||||||||||
Administer ONE of the following antiplatelet agents (before or at the time of PCI):
Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding
Administer ONE of the following anticoagulant therapy:
| Administer ONE of the following antiplatelet agents (before OR at the time of PCI) Before PCI
OR
OR
| Administer ONE of the following antiplatelet agents: ❑ Clopidogrel (I-B)
❑ Ticagrelor (I-B)
| |||||||||||||||||||||||||
❑ Perform an angiography | Does the patient experience any of the following? ❑ Recurrence of symptoms | ||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||
❑ Perform an angiography Administer upstream antiplatelet agent:
❑ IV GP IIb/IIIa inhibitors
| ❑ Perform a stress test | ||||||||||||||||||||||||||
Low risk on stress test | High risk on stress test | ||||||||||||||||||||||||||
❑ Perform an angiography | |||||||||||||||||||||||||||
❑ Continue aspirin for life ❑ Continue P2Y12 receptor inhibitors up to 12 months
❑ Discontinue GP IIb/IIIa inhibitors
| |||||||||||||||||||||||||||
- ↑ Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE; et al. (2012). "2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. 60 (7): 645–81. doi:10.1016/j.jacc.2012.06.004. PMID 22809746.
- ↑ "ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI".